Endocrine Abstracts

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are an extremely heterogenous group of diseases with complicated treatment and management decisions. For example, patients with Multiple Endocrine Neoplasia Type 1 (MEN1)-associated gastrinomas present with more aggressive tumors and poorer outcomes. Recent work has shown that sequencing (transcriptomic, proteomic) can phenotype GEP-NETs to accurately reflect important clinical parameters such as tumor aggress...